Files and links (1)
Accepted (AM)Open Access (License Unspecified), Open
Journal article
Gender differences in the real-world effectiveness of smoking cessation medications: Findings from the 2010-2011 Tobacco Use Supplement to the Current Population Survey
Drug and alcohol dependence, v 178, pp 485-491
01 Sep 2017
PMID: 28715776
Featured in Collection : UN Sustainable Development Goals @ Drexel
Abstract
Background: Meta-analyses of clinical trial data have identified clinically relevant gender differences in the efficacy of smoking cessation pharmacotherapy. It is unclear whether these findings are generalizable to smokers quitting in real-world contexts.
Methods: Using Tobacco Use Supplement to the Current Population Survey (TUS-CPS) 2010-2011 cross-sectional data, we generated propensity score matched samples of smokers who quit either unassisted by medication, using only varenicline, or using only transdermal nicotine patch (TNP). We used generalized estimating equations to estimate gender differences in the comparative effectiveness of these cessation options for achieving 30-days of abstinence, adjusting for potential confounders.
Results: When stratified by gender, TNP was significantly more effective than unassisted quit attempts for men (OR = 1.37; 95%CI = 1.02,1.83; p = 0.03), but not for women (OR = 0.96; 95%CI = 0.71,1.31; p = 0.82). Varenicline was significantly more effective than unassisted quit attempts for women (OR = 1.63; 95%CI = 1.16, 2.31; p = 0.005), but not men (OR = 1.35; 95%CI = 0.94,1.96; p = 0.11). Varenicline was also more effective than TNP for women (OR = 1.51; 95%CI = 0.12,2.05; p = 0.007) but not men (OR = 0.92; 95%CI = 0.65,1.31; p = 0.64). A significant gender by medication interaction was found only for the comparison of varenicline to TNP (OR = 1.64; 95%CI = 1.04,2.61; p = 0.04).
Conclusions: Findings for varenicline vs. TNP were consistent with clinical trial data, showing greater differences in effectiveness for women compared to men. Results lend support to the generalizability of clinical trial findings, highlighting the importance of considering gender when offering treatment for smoking cessation.
Metrics
Details
- Title
- Gender differences in the real-world effectiveness of smoking cessation medications: Findings from the 2010-2011 Tobacco Use Supplement to the Current Population Survey
- Creators
- Philip H. Smith - CUNY School of LawJu Zhang - Yale UniversityAndrea H. Weinberger - Yeshiva UniversityCarolyn M. Mazure - Yale UniversitySherry A. McKee - Yale University
- Publication Details
- Drug and alcohol dependence, v 178, pp 485-491
- Publisher
- Elsevier
- Number of pages
- 7
- Grant note
- Grace J. Fippinger Foundation R03DA040093 / NATIONAL INSTITUTE ON DRUG ABUSE; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA; NIH National Institute on Drug Abuse (NIDA); European Commission R03DA040093; P50DA033945; K12DA031050 / NIH; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA
- Resource Type
- Journal article
- Language
- English
- Academic Unit
- A.J. Drexel Autism Institute
- Web of Science ID
- WOS:000409152300067
- Scopus ID
- 2-s2.0-85030570538
- Other Identifier
- 991022031024504721
UN Sustainable Development Goals (SDGs)
This publication has contributed to the advancement of the following goals:
InCites Highlights
Data related to this publication, from InCites Benchmarking & Analytics tool:
- Collaboration types
- Domestic collaboration
- Web of Science research areas
- Psychiatry
- Substance Abuse